LunaRx Review: Pricing, Process, and Who It's For
An honest, structured look at LunaRx's compounded GLP-1 program — how the care model works, how pricing works, and what to verify before you start.
Disclosure
The GLP Journal is published by LunaRx. This review is written with that conflict of interest disclosed openly. We believe transparency beats pretending independence. This is not medical advice. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances.
Because we publish this review and LunaRx, we'll be direct about what we're evaluating and why. LunaRx is a telehealth brand for GLP-1 weight care. Clinical services and fulfillment run through a third-party partner network rather than in-house, and the medication dispensed is compounded semaglutide or tirzepatide prepared by 503A and 503B partner facilities — not the FDA-approved branded product. That single fact matters more than anything else in this review, so read the regulatory section below before the pricing section.
How does the LunaRx care model work?
The flow is standard telehealth. You complete an intake questionnaire. Depending on your state, you then have either a live (synchronous) consultation or a store-and-forward (asynchronous) review. A licensed physician reviews your intake and independently decides whether to prescribe — they can and do decline. If approved, a licensed pharmacy dispenses and ships to you.
Two things follow from that structure. The clinician is not a LunaRx employee making a sales decision, which is the point of the separation. But it also means LunaRx does not control the clinical call, so ask the prescriber your clinical questions directly rather than asking support. The stated differentiator is a 'come off clean' focus — the service frames GLP-1s as a tool with an exit, not a lifelong subscription.
How much does LunaRx cost?
LunaRx uses tiered pricing rather than a single flat rate. The exact tiers and what's included at each level should be confirmed on the eligibility page, because pricing and what's bundled changes. Ask specifically about monthly cost, shipping, and any program or membership fees.
What are the tradeoffs with LunaRx?
- Pros: clinician-led model; explicit coming-off support; transparent about being a LunaRx publication.
- Cons to verify: the medication is compounded, so it is not FDA-approved and was not the product studied in any trial cited on this site. Since the shortages were resolved in 2025, both compounding pathways narrowed sharply — ask directly what basis applies to your prescription. Tier pricing needs itemization. And like all telehealth, it is remote, which is not a substitute for in-person care when you need it.
Who is LunaRx a good fit for?
People who want a GLP-1 with a clinician in the loop, a clear path to taper, and a price they can itemize. If you need in-person monitoring or have complex comorbidities, talk to your primary clinician first.
Bottom line
LunaRx is a telehealth GLP-1 service with a clinician-led model and an explicit coming-off focus. It uses compounded supply, which is not FDA-approved and which — since the shortages were resolved in 2025 — is only appropriate where a prescriber documents a clinically significant difference for you specifically. Ask for that reasoning before you start. We disclose that we publish this review. This is not a recommendation; it is information, and you should verify pricing, supply, and fit for your situation.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 2.Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
- 3.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.